Introduction
Pregabalin (PGB: (S)-3-(aminomethyl)-5-methylhexanoic acid, CI-1008, S(+)-3-isobutyl GABA) is a new anti-epileptic drug that was licensed in Europe in 2004 as adjunctive therapy for partial epilepsy. Its mechanism of action in epilepsy appears, like gabapentin, to rest upon the reduction of neurotransmitter release at synapses, by binding to the a2-d protein, an auxiliary subunit of voltage-gated calcium channels (for a review see Ref. 1) . PGB has been reported to have a broad spectrum of action and a good safety profile, significantly reducing the frequency of partial seizures in several double-blind randomized clinical trials. [2] [3] [4] [5] [6] The improvement rates in these studies that included highly refractory patients ranged between 17.4% and 39.5%. No interactions with other drugs have been reported. Mild to moderate dose-related adverse events have been reported, including dizziness, ataxia, weight gain, somnolence, asthenia and peripheral oedema. In addition to epilepsy, PGB has also been shown useful for the treatment of pain in diabetic neuropathy, 7, 8 post-herpetic neuralgia in adults, 9,10 fibromyalgia, 11 and more recently, for the treatment of anxiety disorders. [12] [13] [14] [15] [16] In an early cohort of patients prescribed PGB for epilepsy in standard out-patients clinical settings, we assessed outcome looking at seizure freedom, improvement in seizures, retention rate and side effects.
Introduction: Pregabalin (PGB) was licensed in the EU in 2004 as an adjunctive therapy in partial epilepsy. It is also licensed for neuropathic pain and generalised anxiety. Aims: To identify the clinical usefulness and side effects of add-on PGB in out-patient epilepsy clinics. Methods: We performed an audit on 96 consecutive patients (44 male) prescribed PGB for refractory epilepsy. Mean follow-up, for those who remained on PGB, was 23 months (range 12-39 months). Results: Fifty patients remained on PGB, 37 of whom reported clear improvement in seizure frequency. Among these 37 patients, 1 was seizure free for 15 months; 29 had a seizure reduction of >50%; and 7 improved by <50%. Eight patients reported a decrease in seizure severity without change in seizure frequency. Nine patients reported an incidental improvement in anxiety.
Side effects were reported by 25 patients out of the 50 patients still on treatment: 12 reported drowsiness or tiredness, 8 weight gain, 7 dizziness, 2 headache, 2 cognitive side effects, 1 irritability, 1 itchiness, 1 anxiety, and 1 transient rash.
Among the 46 patients who discontinued treatment, 9 had worsening of seizure frequency, 27 lack of efficacy and 9 intolerable side effects necessitating withdrawal (4 dizziness or drowsiness, 2 weight gain, 1 peripheral oedema, 1 pain in arms and legs, 1 irritability and cognitive side effects). One patient had a seizure related death (probably drowning) within 1 month of starting PGB. Conclusion: Pregabalin seems to be an effective and well-tolerated anti-epileptic drug when used as addon treatment in patients with refractory partial epilepsy.
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Methods

Patients
This audit comprises the outcome of the first 96 patients commencing on PGB as adjunctive therapy for partial epilepsy from the South East of UK (Kent and Canterbury Hospital, King's College Hospital NHS Foundation Trust, Maidstone and Tunbridge Wells NHS Trust, Dartford and Gravesham NHS Trust, and Kent and Medway and Social Care Partnership Trust). Only patients still on PGB with a minimum follow-up of 12 months were considered for this audit.
Audit method
Patients were followed up in clinic as per usual practice. An electronic clinical database was set up with data obtained by review of the medical notes, including seizure types, epilepsy syndrome, aetiology, duration of epilepsy, seizure frequency, anti-epileptic medication, both previous and current and PGB use. There was no alteration in on-going care. Patients were started on PGB between July 2004 and December 2006.
Response to treatment was rated as follows: seizure control (100% seizure remission); decrease in seizures by >50% (responder); decrease in seizures by <50% (partial responder); improvement in seizure pattern, unchanged, or worsened seizures. All recorded side effects were noted as well as the main reason for PGB withdrawal.
Results
The cohort
There were 96 patients, 44 male and 52 female with an age range of 21-84 years (mean 43.5). Eighty-five patients were classified as having focal symptomatic epilepsy, 2 patients as idiopathic generalised epilepsy (both with generalised tonicclonic seizures and absences), 1 had Lennox-Gastaut syndrome, and 8 patients were unclassified (7 with generalised tonic-clonic seizures and 1 with complex partial seizures and myoclonic jerks). Seizures were refractory, with a median number of seizures per month of 12 (1-400). The number of other anti-epileptic drugs, excluding as required benzodiazepines, taken by patients at the time of commencing PGB ranged from 0 to 4 (median 2). The minimum number of other anti-epileptic drugs ever taken before commencing PGB, excluding as required benzodiazepines, ranged from 1 to 9 (median 3).
Follow-up and overall outcome
Among the 96 patients, 62 patients (65%) continued taking PGB in the initial follow-up period of 12 months (Fig. 1) , and among them, 50 remained on PGB at the time of last review (up to 39 months, mean 23 months). Among these 50 patients, 37 had a clear reduction in seizure frequency, including 1 patient who was seizure free for 15 months. Twenty-nine patients had seizure reduction by more than 50% (responders) and 7 by less than 50% (partial responders). Eight patients reported improvement in seizure pattern, with less severe seizures, but without clear change in frequency. Five patients did not show any overall reduction in seizure frequency or any improvement in seizure severity, and PGB is being withdrawn. Among the 50 patients remaining on PGB, 9 reported a reduction of anxiety (typically expressed as an improvement in mood) and 7 had a reduction in the number of other anti-epileptic drugs.
The mean maintenance dose of PGB was 187.5 mg (range 25-600). Different titration schemes were used in different centres. The most frequent initial dose of PGB was 25 mg twice/day or less, with subsequent titration according to clinical effects. At Maidstone and Tunbridge Wells NHS Trust, and at Dartford and Gravesham NHS Trust, the initial dose of 75 mg twice/day recommended by the manufacturers was used.
Daily doses of PGB in the seizure free patient was 450 mg. Responders were on a mean dose of 291 mg (range 50-600) and partial responders on 300 mg (range 100-500).
Withdrawal
Forty-six patients no longer remained on PGB. Twenty-seven discontinued because of lack of efficacy, 9 because intolerable side effects (4 dizziness or drowsiness, 2 weight gain, 1 peripheral oedema, 1 pain in arms and legs, 1 irritability and cognitive side effects), 9 had worsening of seizure frequency and 1 had a seizure related death (probably drowning) within 1 month of starting PGB. One patient was completely seizure free for more than 6 months, but withdrew PGB due to side effects (weight gain and pain in arms and legs). Six out of the eight patients with unclassified epilepsy and the 2 patients with IGE withdrew PGB due to lack of efficacy.
Side effects
Side effects were generally mild to moderate in severity. Among the 50 patients still on treatment, 25 patients (50%) reported no side effects at any time, 12 reported drowsiness or tiredness, 8 reported weight gain, 8 reported dizziness, 2 reported some cognitive side effects, 2 reported headache, 1 reported irritability, 1 reported itchiness, 1 reported anxiety, and 1 reported a transient rash. An improvement in mood was reported in nine patients.
Among the 46 patients who withdrew PGB, 11 patients reported no side effects at any time, 3 reported drowsiness or tiredness, 6 reported weight gain, 5 reported dizziness, 3 reported cognitive side effects, and 2 irritability. Other reported side effects were: itchiness, hallucinations, nausea, worsening in memory, dry mouth, worse postictal state, tachycardia, palpitations and pain in limbs. An improvement in mood was reported in two patients. Not clear synergy regarding side effects was seen between PGB and other anti-epileptic drugs.
Discussion
The audit included refractory cases of epilepsy as it is based upon the first 96 patients to start PGB close to the time of licensing of the drug and reflects experience in a clinical setting. Our study confirms previous data about efficacy and tolerability of PGB provided by controlled and audit studies. 4, 17 We found PGB to be efficacious in this cohort of highly refractory epileptic patients. The 65% retention rate of PGB in patients with a follow-up of 1 year is similar to the retention rated described in other audit studies. 3 Among the 50 patients still on PGB, 30 patients showed a clear improvement (>50%) of the seizure frequency, and another 15 were partial responders or reported an improvement in severity of seizures. The recommended starting dose of PGB in the treatment of epilepsy is 75 mg twice/day and, in controlled trials, upward titration of this dose correlates with increased treatment effect. However, initial doses of PGB in the current audit were usually lower than those recommended as it was anticipated that initial low doses and slow titration could minimize withdrawal. In addition, informally we observed that a few patients with early benefit worsened on higher doses. It is possible that this reflects a therapeutic window phenomenon but more data would be required to confirm this.
We confirmed that PGB is generally well tolerated. Early side effects, most commonly dizziness or drowsiness/tiredness, were often transient, but were responsible for the withdrawn of PGB in some cases. Among other relatively frequent side effects, weight gain was reported in 14 patients, and was the main reason for withdrawl of PGB in five. A positive side effect that improved quality of life was reduction of anxiety; this was clearly reported by 11 patients, 9 of them still in PGB. Patients typically expressed this as ''improvement of mood'', ''being happier'' or ''less stress''. In summary, PGB seems an effective and well-tolerated AED when used as add-on treatment in standard out-patient epilepsy clinics. In our study we found that, with a mean follow-up of 23 months, PGB may decrease seizure frequency by more than 50% in around 30% of the patients, and produce an improvement in the pattern of seizures in 15% of the patients. Some responders were able to reduce other AEDs but none achieved monotherapy. Further studies would be needed to assess the whether PGB might be effective as monotherapy in similar patient groups.
